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Purpose
Despite the rapid improvement in survival rate from Burkitt lymphoma and mature B-cell
lymphoblastic leukemia (B-ALL) in children, a small subset of patients do not respond to
first-line chemotherapy or experience relapse (RL). Herein, we report the clinical character-
istics and outcomes of these patients.
Materials and Methods
RL or refractory Burkitt lymphoma and mature B-ALL in 125 patients diagnosed from 1990
to 2009 were retrospectively analyzed.
Results
Nineteen patients experienced RL or progressive disease (PD). Among them, 12 patients
had PD or RL less than six months after initial treatment and seven had late RL. Seven
patients achieved complete response (CR), 11 had PD, and one had no more therapy. Six
patients who achieved CR survived without evidence of disease and four of them underwent
high-dose chemotherapy (HDC) followed by stem cell transplantation (SCT). However, 11
patients who failed to obtain CR eventually died of their disease. Five-year overall survival
(OS) was 31.6±10.7%. OS of patients with late RL was superior to that of patients with early
RL (57.1±18.7%, vs. 16.7±10.8%, p=0.014). Achievement of CR after reinduction had
significant OS (p < 0.001). OS for patients who were transplanted was superior (p < 0.01).
In multivariate analysis, achievement of CR after reinduction chemotherapy showed an
association with improved OS (p=0.05). 
Conclusion
Late RL and chemotherapy-sensitive patients have the chance to achieve continuous CR
using HDC/SCT, whereas patients who are refractory to retrieval therapy have poor
prognosis. Therefore, novel salvage strategy is required for improvement of survival for this
small set of patients.
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Introduction
With the introduction of highly intensive and multiagent
chemotherapy, the survival rate from Burkitt lymphoma has
improved dramatically to > 90% [1-4]. In an international
cooperative study, patients with central nervous system
(CNS)-positive and/or mature B-cell acute lymphoblastic
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leukemia (B-ALL), who had far advanced disease, were
shown to have a cure rate of 80-90% with the addition of
high-dose methotrexate (total dose, 24 g/m2), high-dose
cytarabine arabinoside (Ara-C; total dose, 25.5 g/m2), and
etoposide (VP16; total dose, 2,500 mg/m2) [1,5]. However,
patients with relapse or who are refractory to first-line
treatment have poor prognosis [6-12], and there are few
reports on the incidence and treatment of relapsed or
refractory pediatric Burkitt lymphoma and mature B-ALL.
In 2004, the Korean Society of Pediatric Hematology-
Oncology retrospectively analyzed the incidence, pathologic
subtypes, treatment strategies, and survival rate of children
with malignant lymphoma. However, the incidence and
outcome of relapsed or refractory disease according to
pathologic subtypes were not reported. Here, we report the
characteristics and clinical outcomes of relapsed or refractory
pediatric Burkitt lymphoma and mature B-ALL.
Materials and Methods
A total of 131 patients diagnosed with Burkitt lymphoma
and mature B-ALL at five institutions between January 1990
and December 2009 were included in the current study. Six
patients, including three who were discharged against
medical advice, one whose medical record was lost, and two
who were lost during follow-up were excluded from the
analysis. Medical records of 125 patients were retrospectively
reviewed for comparison of survival outcome. This study
was approved by the institutional review board at each
university hospital.
1. Response criteria
International Working Group recommendations were used
to define response after treatment [13]. Disease status was
determined based on bone marrow (BM) biopsy,
cerebrospinal fluid (CSF) examination, and imaging studies.
Complete response (CR) was defined as disappearance of
symptoms and lesions detected by computed tomography
or magnetic resonance imaging at diagnosis and
normalization of CSF and BM. Partial remission (PR) was any
response less than CR in the absence of progressive disease
(PD), while PD was an increase in size > 25% in the product
of the two largest dimensions or increase in the numbers of
CSF and/or BM blasts. Relapse was defined as appearance
of new lesions, blasts in the CSF or excess of blasts in the BM
after CR.
Relapses were classified as early and late, with cut-off
duration of six months. Time to relapse was the duration
between the start day of chemotherapy or radiotherapy and
the diagnosis of relapse.
2. First-line chemotherapy protocols
Various chemotherapy protocols were chosen according to
each institution’s decision. The lymphoma malignancy B
(LMB) protocol of the Society of French Pediatric Oncology
(SFOP) was most commonly used: LMB 89 or 96 [14]
protocols in eight patients, LMB 81 [15] in one, Children’s
Cancer Group (CCG) 106B [16] in six, daunomycin-
cyclophosphamide, vincristine, methotrexate, and pred-
nisolone (D-COMP) [17] in two, LSA2-L2 [18] in one, and
Berlin-Frankfurt-Munster 90 [19] in one.
3. Statistical analysis
Event-free survival (EFS) from the date of diagnosis to the
date of relapse/progress or death and overall survival (OS)
from the date of diagnosis to the date of last follow-up were
calculated using the Kaplan-Meier method. Heterogeneity of
survival curves was compared using the log-rank method.
Cox’s proportional hazards regression was used to fit a
model for variables found significant by univariate analysis.
p < 0.05 was considered significant. SPSS ver. 13.0 (SPSS Inc.,
Chicago, IL) was used for statistical analysis.  
Results
During the study, 19 of 125 patients (15%) experienced
relapse or progression. The characteristics, treatment, and
outcome of 19 patients are shown in Table 1. The median age
of patients experiencing relapse or refractory disease at initial
diagnosis was 8.8 years (range, 2.1 to 13.8 years) with a male
predominance (17:2). Six patients initially presented with
stage III and 13 presented with stage IV (including seven
CNS-positive). Three patients had primary refractory disease
and 16 patients experienced relapse. Median time to relapse
was five months (range, 2 to 117 months). Sites of relapse or
progress included the primary sites in 14 and new sites in
five cases. Descending frequency was as follows: CNS
(n=10), BM (n=8), abdomen (n=8), and lungs (n=2). The
median lactate dehydrogenase level at diagnosis was 1,080
IU/L (range, 214 to 10,374 IU/L). Seven patients with
available cytogenetic data had various cytogenetic
abnormalities, including t(8;14)(q24;q32), except one (46, XY). 
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1. Response to first-line therapy
Three patients had progression, nine developed early
relapse, and seven developed late relapse. Median survival
for patients with PD or early relapse was three months
(range, 0 to 130 months) and two are alive with CR. These
two patients had isolated CNS relapse. Median time to
relapse for late relapse was nine months (range, 6 to 117
months) and median survival had not been reached.
2. Salvage therapy after relapse or refractory disease 
Two patients with PD received CCG 106B induction
chemotherapy or rituximab but showed no response to
reinduction chemotherapy and eventually died of disease
within three months from the time of progression. Most
frequently used reinduction chemotherapy in patients with
relapse was CCG 106B induction used in five patients, two of
whom achieved CR, one had PR, and two had PD. Other
reinduction chemotherapy included high-dose cytarabine
arabinoside, cyclophosphamide, oncovin, methotrexate
chemotherapy used in three patients, CCG 1882B induction
chemotherapy used in two patients, LMB 89 or 96 used in two
patients, ifosfamide, carboplatin, etoposide (ICE) plus weekly
rituximab used in one patient, and so on (see Table 1). As a
response to reinduction chemotherapy seven patients
achieved CR and three of them received high-dose chemother-
apy (HDC) followed by autologous stem cell transplantation
(ASCT), and drugs used in the HDC included bis-chloroethyl-
nitrosourea or nimustin, etoposide, and cyclophosphamide in
two patients and carboplatin and ifosfamide in one patient.
One patient with mature B-ALL had fludarabine, cyclophos-
phamide and total body irradiation conditioned unrelated BM
stem cell transplanatation (SCT). A patient (3-14) with multiple
bone metastases who had already received ASCT in first-line
treatment received eight cycles of ICE chemotherapy and 10
doses of rituximab (375 mg/m2/dose) after relapse and was
alive without disease.
3. Outcome after salvage chemotherapy 
Six patients (31.5%) survived, with a median follow-up
period of 86 months (range, 71 to 134 months). Three patients
with PD died of disease. However, seven patients who
achieved CR after salvage therapy are alive, except one (nos.
1-55) without disease. One experienced second CNS relapse
after maintaining short term remission. He received CCG
106B induction chemotherapy and radiotherapy with a dose
of craniospinal irradiation (6 Gy/3Fr) and whole brain
irradiation (18 Gy/9Fr) as a salvage therapy but eventually
died of disease five months after relapse. Nine patients with
PD after salvage therapy died of disease.
The OS and EFS of all 125 patients was 82.4±3.4% and
77.6±3.65%, respectively, whereas those of patients
experiencing relapse or refractory disease was 31.6±10.7%
(Fig. 1A). Significantly improved outcome (85.7±13.2%) was
observed for patients who achieved CR to reinduction
chemotherapy (p < 0.001). 
The OS of early and late relapses was 16.7±10.8% and
57.1±18.7%, respectively (p=0.014) (Fig. 1C). The OS of those
who were transplanted and were not transplanted were
100% and 13.3±8.8%, respectively (p=0.008) (Fig. 1D). To
evaluate the impact of SCT on survival in patients who
achieved CR after salvage therapy we compared the OS of
patients who were transplanted (n=4) and those who were
not transplanted (n=3), but there was no significance
(p=0.25).
Multivariate Cox regression analysis using conditional
parameter estimate showed that achievement of CR after
reinduction chemotherapy was associated with improved OS
(hazard ratio, 0.009; 95% confidence interval, 0.000 to 0.999;
p=0.05) and other variables, including time to relapse and
hematopoietic SCT had no influence on survival outcome.
Discussion
Despite dramatically improved survival over the past few
decades, patients experiencing relapse or refractory disease
continue to have very poor outcomes. The frequency of
relapse vs. progress varies according to first-line treatment
used; therefore, objective comparison is difficult. The
incidence of relapse or refractory disease was reported as
6.4% (9/140) in an Austrian multicenter study [12] and 10.1%
(33/327) in a Japanese multicenter study [8], although the
two groups used different treatment protocols. There are no
data from a nationwide study. In our dataset, 15.2% (19/125)
of patients with Burkitt lymphoma and mature B-ALL
developed relapse or refractory disease. Diffuse large B cell
lymphoma and primary mediastinal lymphoma were not
included in our dataset and various first-line chemotherapy
and reinduction chemotherapy were tried in multicenter
during a long period (1990-2009). 
Despite introduction of heterogenous reinduction
chemotherapies, seven patients achieved CR (CR rate,
36.8%), six of whom are alive without evidence of disease.
Another 12 patients who never responded to salvage
regimens died with rapid disease progression. From this
finding we can infer that responsiveness to retrieval therapy
is a very important factor for survival of this small subset of
patients (p=0.05, multivariate Cox’s regression analysis).
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Fig. 1. (A) Overall survival of relapsed or primary refractory disease. Median survival was seven months (95% confidence
interval [CI], 5.6 to 8.4). (B) Overall survival of patients who achieved complete response (CR) and non-CR to reinduction
chemotherapy, which is statistically significant (p < 0.001). Median survival was 5.5 months (95% CI, 3.4 to 6.6) for patients
who had non-CR. (C) Overall survival and time to relapse. Median survival was five months for patients who had primary
refractory or early relapse. Survival rate for primary refractory or early relapse and late relapse was 16.7±10.8% and 57.1±18.7,
respectively (p < 0.05). (D) Overall survival and hematopoietic stem cell transplantation. Median survival was 6.5 months
(95% CI, 4.6 to 8.4) for patients who were not transplanted. Overall survival of both groups was statistically significant
(p < 0.01).
In our cohort, five patients were assigned to the LMB risk
group C (CNS positive in 3; CNS negative in 2) and received
highly intensive chemotherapy at initial diagnosis (two
cycles of COPADM as induction chemotherapy and CYVE
as consolidation chemotherapy). After relapse, four patients
received 106B reinduction chemotherapy. As a result, only
one CNS-negative patient (nos. 1-64) responded to retrieval
therapy and achieved CR.
Patte et al. [3] reported that among patients in LMB 84
group C (using high-dose methotrexate, high-dose Ara-C,
and VP16), there were no survivors in patients whose tumors
did not respond to the prephase chemotherapy, meaning that
Su
rv
iv
al
 p
ro
ba
bi
lit
y
1.0
0.8
0.6
0.4
0.2
0
0 20 40 60 80 100 120
Time (mo)
140
A B
CR (n=7)
Non-CR (n=12)
C D
Su
rv
iv
al
 p
ro
ba
bi
lit
y
1.0
0.8
0.6
0.4
0.2
0
0 20 40 60 80 100 120
Time (mo)
140
Yes (n=4)
No (n=15)
Late response (n=7)
Early relapse or progressive disease (n=12)
Su
rv
iv
al
 p
ro
ba
bi
lit
y
1.0
0.8
0.6
0.4
0.2
0
0 20 40 60 80 100 120
Time (mo)
140
Su
rv
iv
al
 p
ro
ba
bi
lit
y
1.0
0.8
0.6
0.4
0.2
0
0 20 40 60 80 100 120
Time (mo)
140
학회지(46-4)_in  14. 10. 8.  오후 1:19  페이지 362
VOLUME 46  NUMBER 4  OCTOBER  2014  363
Hyery Kim, Relapsed or Refractory Burkitt lymphoma and B-ALL
patients who failed to achieve remission with this intense
first-line treatment receive virtually no benefit from
HDC/SCT. Anoop et al. [20] recently reported that all 10
relapsed patients in group C (LMB 96 and UKCCSG2003)
died despite receiving various reinduction treatments.
Considering the high morbidity and mortality rates of LMB
89/96 protocols group C, we must refine the first-line
treatments without compromising the current survival
outcome. Cytogenetic and molecular data should be
incorporated in stratification of patients and tailored
treatment including rituximab and/or HDC/SCT is
warranted in the near future.
Because a correlation between response to initial retrieval
therapy and survival is evident, guaranteed salvage
regimens should be chosen for treatment of relapse or
refractory disease. Various retrieval therapies have been tried
to this point. The DECAL regimen (dexamethasone,
etoposide, cisplatin, cytarabine arabinoside, L-asparaginase)
used by the CCG 5912 had a 50% response rate and a 30%
2-year OS that was independent of pathologic subtypes [21].
The ICE regimen (ifosfamide, carboplatin, and etoposide)
used by the Pediatric Oncology Group had a 71% CR/PR
rate, but long-term outcomes were not reported [10]. Another
combination of rituximab plus ICE chemotherapy was used
by the CCG and a 64% (9/14) CR/PR rate was reported.
Responders to salvage treatment had significantly longer OS
than patients who did not respond to treatment [21]. In
addition, recently published data showed that rituximab (375
mg/m2/dose) is an important parameter affecting survival
and four doses of rituximab (total dose 1,500 mg/m2) showed
an association with improved survival in regression analysis.
Responsiveness to retrieval therapy is a prerequisite for
survival in patients experiencing relapse or refractory
disease. Some benefits seem to be achieved by consolidative
therapy using HDC/SCT in only a portion of patients who
responded to salvage therapy [8,11,22]. 
If we can predict the risk of relapse or lack of response to
chemotherapy at the beginning of first-line therapy, other
treatment options such as HDC/SCT used with or without
immunotherapy can be used at the time of initial diagnosis,
which will be ideal for this dismal subset of patients. The
importance of cytogenetic data was recently accentuated.
More than 80% of Burkitt lymphoma and mature B-ALL
patients are known to have the MYC/8q24 rearrangement.
In addition to the MYC/8q24 rearrangement, other
chromosomal aberrations have been described in 60-90% of
Burkitt lymphoma [23]; these abnormalities are reported to
be associated with tumor progression [24]. Association of
cytogenetic abnormalities such as del(13q), +7q, complexity,
and aneuploidy with a worse outcome has been reported
[25], but a more comprehensive analysis of the correlation
between chromosomal aberrations and clinical outcome with
a larger number of patients is warranted for adjustment of
cytogenetic risk-adapted therapy. Unfortunately, cytogenetic
data in our patient set was not informative due to missing or
unchecked data in a large portion of patients. In the future,
cytogenetic data should be included as a basic component of
initial diagnosis and also incorporated with treatment
stratification.
Conclusion
Because efficient drugs have already been escalated to
front-line therapy, new therapeutic approaches that are
adjusted according to biological cancer cell behavior using
cytogenetic and molecular data, such as ICE or CYVE
chemotherapy plus rituximab and/or ASCT or allogeneic
SCT, are needed for high-risk patients. Use of HDC/SCT
might be beneficial for patients with relapsed or refractory
disease who are responding to retrieval chemotherapy.
Conduct of more observational study using a large cohort is
warranted in order to estimate efficacy of these approaches.
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